Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Merck
Merck
Merck Covid antiviral pill did not cut hospitalization risk, study finds
Financial Times
Sun, 10/9/22 - 06:08 pm
Merck
COVID-19
molnupiravir
Merck KGaA says it'll consider 'larger-scale' acquisitions from 2023 onward
Fierce Pharma
Thu, 10/6/22 - 07:08 pm
Merck
KGaA
M&A
Merck's $500M bet on Singapore leads to new manufacturing sites making Keytruda, Gardasil and future inhalers
Endpoints
Thu, 10/6/22 - 10:38 am
Merck
Singapore
drug manufacturing
Merck celebrates another win in Januvia patent battle against Viatris
Endpoints
Sun, 10/2/22 - 07:46 pm
Merck
Januvia
patents
legal
diabetes
Viatris
Keytruda taught Merck how to build a blockbuster. But manufacturing a 2nd lightning bolt is easier said than done
Fierce Pharma
Thu, 09/29/22 - 07:42 pm
Merck
Keytruda
cancer
oncology
ESMO
Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
BioPharma Dive
Mon, 09/26/22 - 11:20 pm
Seagen
Merck
Lava Therapeutics
bispecific antibodies
LAVA-1223
AstraZeneca, Merck withdraw Lynparza's late-line ovarian cancer nod amid PARP inhibitor death concerns
Fierce Pharma
Sun, 09/25/22 - 02:28 pm
AstraZeneca
Merck
Lynparza
ovarian cancer
Merck pulls a patent win for diabetes franchise in West Virginia federal court
Endpoints
Thu, 09/22/22 - 11:12 pm
Merck
Januvia
Janumet
generics
legal
Viatris
Merck finally gets FDA nod to relaunch HIV trials, but drops preventive therapy plans
Fierce Biotech
Tue, 09/20/22 - 10:26 am
Merck
FDA
clinical trials
islatravir
Seagen secures a speedy FDA review on Tukysa as Merck buyout talks reportedly stall
Endpoints
Mon, 09/19/22 - 10:02 pm
Seagen
Merck
M&A
Tukysa
Bristol Myers' Opdivo win tees up showdown with Keytruda in earlier-stage melanoma
Fierce Pharma
Thu, 09/15/22 - 11:15 pm
Merck
Keytruda
Bristol Myers Squibb
Opdivo
melanoma
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
Mon, 09/12/22 - 10:57 am
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
ESMO: Merck's Keytruda chalks up failure in head and neck cancer. But experts see silver lining
Fierce Pharma
Mon, 09/12/22 - 10:52 am
Merck
Keytruda
head and neck cancer
ESMO
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Thu, 09/8/22 - 04:40 pm
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
ESMO 2022 – the new liver cancer entrants line up
EP Vantage
Thu, 09/8/22 - 10:39 am
ESMO
liver cancer
Keytruda
tislelizumab
camrelizumab
Merck
BeiGene
Novartis
ESMO 2022 – Keytruda secures a renal cancer monopoly
EP Vantage
Thu, 09/8/22 - 12:03 am
Merck
Keytruda
renal cancer
Bristol Myers Squibb
Roche
ESMO
Merck's Deal With Seagen May Have Fallen Through. Now What?
Motley Fool
Wed, 09/7/22 - 10:16 am
Merck
Seagen
M&A
Merck and Seagen can't agree on a price for their rumored merger
Fierce Pharma
Fri, 08/26/22 - 10:43 am
M&A
Merck
Seagen
Merck backs radiopharmaceutical startup Aktis, joining other high-profile backers
BioPharma Dive
Thu, 08/25/22 - 10:55 am
Aktis Oncology
radiopharmaceuticals
Merck
Novartis
Bristol Myers Squibb
Merck, seeking XI factor in race with Bayer, gets FDA fast-track tag for anticoagulant
Fierce Biotech
Tue, 08/23/22 - 10:32 am
Merck
Bayer
FDA
MK-2060
end-stage renal disease
ESRD
bloodthinners
Pages
« first
‹ previous
…
10
11
12
13
14
15
16
17
18
…
next ›
last »